Table 5.
Novel significant loci identified by the proposed joint test methods
| SNP | Chr | Gene | OT | ET | AT | minP-2010 | minP-2013 | |
|---|---|---|---|---|---|---|---|---|
| rs6730449 | 2 | DYNC2LI1 | 5.75 e-07 | 1.72 e-08 | 3.72 e-08 | 1.83 e-07 | 2.43 e-06 | |
| rs762861 | 4 | HGFAC | 1.52 e-07 | 2.74 e-08 | 4.72 e-08 | 9.15 e-07 | 5.04 e-07 | |
| rs7705104 | 5 | PELO | 2.38 e-08 | 9.07 e-01 | 5.12 e-08 | 1.72 e-02 | — | |
| rs10462958 | 5 | TIMD4 | 7.02 e-07 | 2.99 e-08 | 6.42 e-08 | 2.03 e-07 | — | |
| rs499921 | 6 | FRK | 4.99 e-07 | 2.70 e-08 | 5.80 e-08 | 1.81 e-07 | 5.07 e-08 | |
| rs12667186 | 7 | SP4 | 9.69 e-07 | 3.14 e-08 | 6.75 e-08 | 1.36 e-07 | 1.08 e-07 | |
| rs17148062 | 7 | POT1 | 4.66 e-08 | 7.65 e-01 | 9.98 e-08 | 6.14 e-02 | — | |
| rs4455806 | 8 | SOX17 | 1.29 e-06 | 4.60 e-08 | 9.85 e-08 | 1.84 e-07 | 5.09 e-08 | |
| rs10090964 | 8 | SDCBP | 5.78 e-07 | 2.98 e-08 | 6.40 e-08 | 5.09 e-08 | 7.37 e-08 | |
| rs4573621 | 10 | GPAM | 4.54 e-08 | 4.14 e-02 | 9.72 e-08 | 2.70 e-04 | 2.09 e-04 | |
| rs4238103 | 12 | LARP4 | 4.08 e-09 | 9.05 e-02 | 4.08 e-09 | 3.83 e-04 | — | |
| rs9600211 | 13 | KLF12 | 1.57 e-09 | 1.88 e-01 | 1.57 e-09 | 1.52 e-05 | — | |
| rs4419034 | 15 | FRMD5 | 4.87 e-08 | 4.30 e-01 | 1.04 e-07 | 5.05 e-08 | 1.51 e-06 | |
| rs16959082 | 17 | RCVRN | 3.67 e-08 | 5.32 e-02 | 7.87 e-08 | 7.44 e-05 | 4.32 e-01 | |
Note: Listed are the joint test P-values and the minimum marginal test P-values across all traits in Teslovich et al. (2010) and Willer et al. (2013) (denoted as minP-2010 and minP-2013 respectively).